The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.

[1]  C. Porta,et al.  Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. , 2022, The Lancet. Oncology.

[2]  B. Yaremko,et al.  Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) - Extended Long-Term Outcomes. , 2022, International journal of radiation oncology, biology, physics.

[3]  M. Scorsetti,et al.  Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy. , 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  R. Hannan,et al.  Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. , 2021, European urology oncology.

[5]  S. Loi,et al.  Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. , 2021, European urology.

[6]  M. Scorsetti,et al.  The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group , 2021, Clinical & Experimental Metastasis.

[7]  F. Zhou,et al.  Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma , 2021, Radiation oncology.

[8]  E. Jonasch,et al.  Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. , 2021, The Lancet. Oncology.

[9]  F. Lohr,et al.  Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. , 2021, European urology.

[10]  J. Burke,et al.  Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[11]  B. Ahmad,et al.  Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. , 2021, European urology.

[12]  R. Hannan,et al.  Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma , 2021, Advances in radiation oncology.

[13]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[14]  J. Larkin,et al.  Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Nicholas G Zaorsky,et al.  Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.

[16]  T. Powles,et al.  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[17]  N. Lee,et al.  Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Xuan Wu,et al.  What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis , 2020, BMJ Open.

[19]  R. Weichselbaum,et al.  Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease , 2020, Cancer journal.

[20]  D. Song,et al.  Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). , 2020 .

[21]  S. Gamayunov,et al.  Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study , 2019, ESMO Open.

[22]  R. Hannan,et al.  Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. , 2019, International journal of radiation oncology, biology, physics.

[23]  Nicholas G Zaorsky,et al.  Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. , 2019, European urology oncology.

[24]  R.C.E. van Velthoven,et al.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial , 2019, JAMA oncology.

[25]  Joe Y. Chang,et al.  Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.

[26]  G. Calais,et al.  Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. , 2018, European journal of cancer.

[27]  K. Bensalah,et al.  Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[28]  U. Harmenberg,et al.  Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[30]  G. Bauman,et al.  A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma , 2018, Radiation Oncology.

[31]  I. Kaplan,et al.  Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK) , 2018, Cancer.

[32]  A. Louie,et al.  Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations , 2016, American journal of clinical oncology.

[33]  E. Goetghebeur,et al.  Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial , 2017, Radiation Oncology.

[34]  B. Slotman,et al.  Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach , 2017, Nature Reviews Urology.

[35]  M. Eble,et al.  Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy". , 2017, Journal of thoracic disease.

[36]  Anurag K. Singh,et al.  A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[37]  S. Signoretti,et al.  Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. , 2017, The oncologist.

[38]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[39]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[40]  E. Lam,et al.  Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT) , 2015, Radiation Oncology.

[41]  Sean S. Park,et al.  PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.

[42]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[43]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[44]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[45]  J. Mechalakos,et al.  Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. , 2012, International journal of radiation oncology, biology, physics.

[46]  R. Weichselbaum,et al.  Oligometastases revisited , 2011, Nature Reviews Clinical Oncology.

[47]  H. Blomgren,et al.  A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma , 2006, Acta oncologica.

[48]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[49]  N. Iizuka,et al.  Nephrectomy in renal carcinoma with distant metastasis. , 1989, British journal of urology.